{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:30:53Z","timestamp":1790465453733,"version":"4.1.0"},"reference-count":231,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.02\/557\/44"],"award-info":[{"award-number":["RGP.02\/557\/44"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pharma.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T06:10:30Z","timestamp":1723875030000},"page":"228-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9443-5997","authenticated-orcid":false,"given":"Shivam","family":"Rajput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6149","authenticated-orcid":false,"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia Obaidur","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Uniyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2024.08.005_bib1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-9597-4_1","article-title":"Introduction to the immune system","volume":"2024","author":"McComb","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharma.2024.08.005_bib1010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharma.2024.08.005_bib1020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.pharma.2024.08.005_bib1025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.blre.2014.10.003","article-title":"Platelet secretion: from haemostasis to wound healing and beyond","volume":"29","author":"Golebiewska","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1035","doi-asserted-by":"crossref","first-page":"2337907","DOI":"10.1080\/09537104.2024.2337907","article-title":"The natural anticoagulant protein S; hemostatic functions and deficiency","volume":"35","author":"Alshehri","year":"2024","journal-title":"Platelets"},{"key":"10.1016\/j.pharma.2024.08.005_bib1040","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2009-05-199208","article-title":"Coagulation and innate immune responses: can we view them separately?","volume":"114","author":"Delvaeye","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1045","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2020007208","article-title":"Disseminated intravascular coagulation and its immune mechanisms","volume":"139","author":"Popescu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/life13020350","article-title":"Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines","volume":"13","author":"Tsantes","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.pharma.2024.08.005_bib1055","doi-asserted-by":"crossref","first-page":"e12728","DOI":"10.1002\/rth2.12728","article-title":"Hemostasis and tumor immunity","volume":"6","author":"Cantrell","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.005_bib1060","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1038\/s41598-024-61194-0","article-title":"Identification of early coagulation changes associated with survival outcomes post severe burns from multiple perspectives","volume":"14","author":"Huang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharma.2024.08.005_bib1065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5482\/ha-1134","article-title":"Coagulation and inflammation","volume":"31","author":"Lipinski","year":"2011","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.pharma.2024.08.005_bib1070","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/01.RES.0000172745.09928.87","article-title":"Soluble tissue factor emerges from inflammation","volume":"96","author":"Ott","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2022.12.005","article-title":"Prognostic importance of biomarkers associated with haemostatic, vascular and endothelial disturbances in acute coronary syndrome patients in relation to kidney function","volume":"373","author":"M\u00f6rtberg","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1080","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/eurheartj\/ehad106","article-title":"Determining \u2018thrombogenicity\u2019in patients with coronary artery disease: what's next?","volume":"44","author":"Iding","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1090","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1056\/NEJMc2010459","article-title":"Acute cor pulmonale in critically ill patients with Covid-19","volume":"382","author":"Creel-Bulos","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1095","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.120.047525","article-title":"ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes","volume":"141","author":"Stefanini","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1100","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial thrombosis\u00a0\u2014\u00a0insidious, unpredictable and deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1105","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2024.08.005_bib1110","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/0115665240258746230919165935","article-title":"The role of tissue factor in signaling pathways of pathological conditions and angiogenesis","volume":"24","author":"Heidari","year":"2024","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00441-021-03471-2","article-title":"Endothelial cells and coagulation","volume":"387","author":"Neubauer","year":"2022","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1120","doi-asserted-by":"crossref","first-page":"100487","DOI":"10.1016\/j.pacs.2023.100487","article-title":"Detection of clot formation & lysis in-vitro using high frequency photoacoustic imaging & frequency analysis","volume":"30","author":"Bodera","year":"2023","journal-title":"Photoacoustics"},{"key":"10.1016\/j.pharma.2024.08.005_bib1125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2009.01128.x","article-title":"Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants","volume":"14","author":"Adams","year":"2009","journal-title":"Nephrology"},{"key":"10.1016\/j.pharma.2024.08.005_bib1130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis: insights from animal models","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.pharma.2024.08.005_bib1140","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3389\/fimmu.2018.01731","article-title":"The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders\u00a0\u2014\u00a0a systematic review","volume":"9","author":"G\u00f6bel","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1145","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/jcm11164932","article-title":"Pathophysiology of coagulation and emerging roles for extracellular vesicles in coagulation cascades and disorders","volume":"11","author":"Al-Koussa","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1538-7836.2011.04323.x","article-title":"Innate immunity and coagulation","volume":"9","author":"Esmon","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1155","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15062","article-title":"Haemostasis and innate immunity\u00a0\u2013\u00a0a complementary relationship: a review of the intricate relationship between coagulation and complement pathways","volume":"180","author":"Keragala","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1160","doi-asserted-by":"crossref","first-page":"e12109","DOI":"10.1002\/rth2.12109","article-title":"The coagulation system in host defense","volume":"2","author":"Antoniak","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1165","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.actbio.2022.10.046","article-title":"Magnesium incorporation in fibrinogen scaffolds promotes macrophage polarization towards M2 phenotype","volume":"155","author":"Bessa-Gon\u00e7alves","year":"2023","journal-title":"Acta Biomater"},{"key":"10.1016\/j.pharma.2024.08.005_bib1170","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/bloodadvances.2017006726","article-title":"Platelet dense granules begin to selectively accumulate mepacrine during proplatelet formation","volume":"1","author":"Hanby","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharma.2024.08.005_bib1180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.thromres.2022.12.004","article-title":"Platelet ageing: a review","volume":"231","author":"Allan","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet \u03b1-granules: basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1190","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/bloodadvances.2020002117","article-title":"Platelet \u03b1-granules are required for occlusive high-shear-rate thrombosis","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharma.2024.08.005_bib1195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/emmm.201100183","article-title":"Chemokines: established and novel targets in atherosclerosis","volume":"3","author":"Koenen","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1200","first-page":"210","article-title":"The role of cytokines and chemokines in the inflammatory response","volume":"10","author":"Harvanov\u00e1","year":"2023","journal-title":"Alergol Pol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2020.04.018","article-title":"Platelet-leukocyte interplay during vascular disease","volume":"307","author":"Schrottmaier","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1210","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.3390\/ijms232112772","article-title":"Platelets and their role in hemostasis and thrombosis\u00a0\u2014\u00a0from physiology to pathophysiology and therapeutic implications","volume":"23","author":"Scridon","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rth2.12454","article-title":"Protease-activated receptors: an illustrated review","volume":"5","author":"Han","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1220","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3389\/fimmu.2019.01311","article-title":"Protease activated receptor 4 as a novel modulator of regulatory T cell function","volume":"10","author":"Peng","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10557-019-06932-7","article-title":"Ticagrelor inhibits toll-like and protease-activated receptor mediated platelet activation in acute coronary syndromes","volume":"34","author":"Wadowski","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharma.2024.08.005_bib1230","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1111\/febs.16406","article-title":"The yin-yang roles of protease-activated receptors in inflammatory signalling and diseases","volume":"289","author":"Zhuo","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1235","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/bph.15587","article-title":"Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019","volume":"179","author":"Subramaniam","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1240","first-page":"1","article-title":"Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1245","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.3390\/ijms24098298","article-title":"Species differences in platelet protease-activated receptors","volume":"24","author":"Renna","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1250","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/a-1336-0526","article-title":"Polyanions in coagulation and thrombosis: focus on polyphosphate and neutrophils extracellular traps","volume":"121","author":"Rangaswamy","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1255","first-page":"319","article-title":"Mechanism action of platelets and crucial blood coagulation pathways in hemostasis","volume":"11","author":"Periayah","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1260","doi-asserted-by":"crossref","first-page":"e12107","DOI":"10.1002\/rth2.12107","article-title":"Integrating platelet and coagulation activation in fibrin clot formation","volume":"2","author":"Swieringa","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00932-z","article-title":"Beyond thrombosis: the impact of tissue factor signaling in cancer","volume":"13","author":"Unruh","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"Ahmadi","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1275","doi-asserted-by":"crossref","first-page":"e0158377","DOI":"10.1371\/journal.pone.0158377","article-title":"The role of putative phosphatidylserine-interactive residues of tissue factor on its coagulant activity at the cell surface","volume":"11","author":"Ansari","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.pharma.2024.08.005_bib1280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"Ahmadi","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1290","doi-asserted-by":"crossref","first-page":"1113827","DOI":"10.3389\/fcvm.2023.1113827","article-title":"The role of monocytes in thrombotic diseases: a review","volume":"10","author":"Han","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/ATVBAHA.121.317176","article-title":"Inflammatory monocyte counts determine venous blood clot formation and resolution","volume":"42","author":"Shahneh","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1300","doi-asserted-by":"crossref","first-page":"H540","DOI":"10.1152\/ajpheart.00336.2014","article-title":"Monocytes regulate systemic coagulation and inflammation in abdominal sepsis","volume":"308","author":"Wang","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1305","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vph.2014.05.005","article-title":"Regulation of tissue factor gene expression in monocytes and endothelial cells: thromboxane A2 as a new player","volume":"62","author":"Bode","year":"2014","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1310","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/cvr\/cvv147","article-title":"Monocyte trafficking across the vessel wall","volume":"107","author":"Gerhardt","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1315","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/j.crvasa.2015.08.002","article-title":"Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development","volume":"58","author":"\u010cejkov\u00e1","year":"2016","journal-title":"Cor et Vasa"},{"key":"10.1016\/j.pharma.2024.08.005_bib1320","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ijms19010092","article-title":"The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis","volume":"19","author":"Hirayama","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1325","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.it.2023.10.004","article-title":"Macrophage phenotypes and functions: resolving inflammation and restoring homeostasis","volume":"44","author":"Rodr\u00edguez-Morales","year":"2023","journal-title":"Trends Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1330","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1335","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.blre.2017.05.001","article-title":"Interleukin-1\u03b2 as emerging therapeutic target in hematological malignancies and potentially in their complications","volume":"31","author":"Arranz","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1340","article-title":"Oxidized low-density lipoprotein changes the inflammatory status and metabolomics profiles in human and mouse macrophages and microglia","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.pharma.2024.08.005_bib1345","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.3390\/ijms22126591","article-title":"Monocytes expose factor XIII-A and stabilize thrombi against fibrinolytic degradation","volume":"22","author":"Alshehri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types?","volume":"9","author":"Rosales","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1355","first-page":"1","article-title":"Neutrophils and neutrophil extracellular traps in cardiovascular disease: an overview and potential therapeutic approaches","volume":"101850","author":"Shirakawa","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharma.2024.08.005_bib1360","doi-asserted-by":"crossref","first-page":"9254087","DOI":"10.1155\/2020\/9254087","article-title":"Neutrophil extracellular traps: signaling properties and disease relevance","volume":"2020","author":"Li","year":"2020","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharma.2024.08.005_bib1365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fimmu.2016.00271","article-title":"Platelets: new bricks in the building of neutrophil extracellular traps","volume":"7","author":"Carestia","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MOH.0000000000000297","article-title":"Platelets in neutrophil recruitment to sites of inflammation","volume":"24","author":"Pitchford","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1375","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/ATVBAHA.122.318767","article-title":"Antagonistic roles of human platelet integrin \u03b1IIb\u03b23 and chemokines in regulating neutrophil activation and fate on arterial thrombi under flow","volume":"43","author":"Sch\u00f6nichen","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1380","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2020008345","article-title":"Impaired adhesion of neutrophils expressing Slc44a2\/HNA-3b to VWF protects against NETosis under venous shear rates","volume":"137","author":"Zirka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1385","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajhg.2015.01.019","article-title":"Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism","volume":"96","author":"Germain","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharma.2024.08.005_bib1390","doi-asserted-by":"crossref","first-page":"12563","DOI":"10.3390\/ijms241612563","article-title":"The crossroads of the coagulation system and the immune system: interactions and connections","volume":"24","author":"Wilhelm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1395","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cells12172120","article-title":"Pathophysiology of disseminated intravascular coagulation in sepsis: a clinically focused overview","volume":"12","author":"Unar","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.pharma.2024.08.005_bib1400","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1158\/2326-6066.CIR-13-0102","article-title":"Dendritic cells: master regulators of the immune response","volume":"1","author":"Mellman","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2332\/allergolint.13-OA-0595","article-title":"Thrombomodulin modulates dendritic cells via both antagonism of high mobility group protein B1 and an independent mechanism","volume":"63","author":"Toda","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.pharma.2024.08.005_bib1410","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4049\/jimmunol.181.2.1215","article-title":"Mature dendritic cells express functional thrombin receptors triggering chemotaxis and CCL18\/pulmonary and activation-regulated chemokine induction","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1415","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/all.14632","article-title":"Advances and novel developments in mechanisms of allergic inflammation","volume":"75","author":"Han","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pharma.2024.08.005_bib1420","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/jcm8030353","article-title":"Prognostic relevance of altered lymphocyte subpopulations in critical illness and sepsis","volume":"8","author":"Hohlstein","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1425","first-page":"34","article-title":"Implications of B lymphocyte dysfunction in HIV\/AIDS","volume":"2","author":"Obeagu","year":"2024","journal-title":"Elite J Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/827254","article-title":"lymphocytes: development, tolerance, and their role in autoimmunity \u2014 focus on systemic lupus erythematosus","volume":"2013","author":"Tob\u00f3n","year":"2013","journal-title":"Autoimmun Dis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1435","first-page":"10","article-title":"The intersection of coagulation activation and inflammation after injury: what you need to know","volume":"96","author":"Costantini","year":"2023","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.pharma.2024.08.005_bib1440","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1538-7836.2009.03417.x","article-title":"Role of regulatory T cells in tolerance to coagulation factors","volume":"7","author":"Cao","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1445","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/geno.1994.1585","article-title":"The organization of the human complement factor I gene (IF): a member of the serine protease gene family","volume":"24","author":"Vyse","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.pharma.2024.08.005_bib1450","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.repc.2013.10.019","article-title":"Immune function of peripheral T cells in patients with venous thromboembolism or coronary artery atherosclerosis","volume":"33","author":"Zhou","year":"2014","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"10.1016\/j.pharma.2024.08.005_bib1455","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCRESAHA.116.309301","article-title":"Innate effector-memory T-cell activation regulates post-thrombotic vein wall inflammation and thrombus resolution","volume":"119","author":"Luther","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1460","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/ijms21051650","article-title":"Depletion of CD4 and CD8 positive T cells impairs venous thrombus resolution in mice","volume":"21","author":"Mukhopadhyay","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1465","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.it.2018.04.010","article-title":"Immune factors in deep vein thrombosis initiation","volume":"39","author":"Budnik","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1470","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjh.15192","article-title":"Acute deep vein thrombosis suppresses peripheral T cell effector function","volume":"184","author":"Prochaska","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fphar.2015.00184","article-title":"Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners","volume":"6","author":"Lei","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1480","doi-asserted-by":"crossref","first-page":"585819","DOI":"10.3389\/fimmu.2020.585819","article-title":"The therapeutic potential of regulatory T cells: challenges and opportunities","volume":"11","author":"Bayati","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1485","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/CIRCULATIONAHA.109.875583","article-title":"Regulatory T cells modulate postischemic neovascularization","volume":"120","author":"Zouggari","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1490","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MOL.0b013e32830bfdc2","article-title":"T cells in arteritis and atherosclerosis","volume":"19","author":"Weyand","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1495","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/HYPERTENSIONAHA.118.12286","article-title":"Novel role of T cells and IL-6 (Interleukin-6) in angiotensin II\u2013induced microvascular dysfunction","volume":"73","author":"Senchenkova","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2024.08.005_bib1500","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/ATVBAHA.119.312467","article-title":"B lymphocytes and adipose tissue inflammation","volume":"40","author":"Srikakulapu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1505","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jcp.2003.007641","article-title":"Molecular biology of squamous cell carcinoma of the head and neck","volume":"59","author":"Perez-Ordonez","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1510","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/17474930221150349","article-title":"Antiphospholipid syndrome, antiphospholipid antibodies, and stroke","volume":"18","author":"Mittal","year":"2023","journal-title":"Int J Stroke"},{"key":"10.1016\/j.pharma.2024.08.005_bib1515","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/blood-2008-10-186452","article-title":"A role for thrombin in the initiation of the immune response to therapeutic factor VIII","volume":"114","author":"Skupsky","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1520","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41371-022-00771-0","article-title":"Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases","volume":"37","author":"Visniauskas","year":"2023","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharma.2024.08.005_bib1525","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3390\/jcm13092668","article-title":"Understanding the pathophysiology of preeclampsia: exploring the role of antiphospholipid antibodies and future directions","volume":"13","author":"Mitranovici","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm12010018","article-title":"B-Cells and BAFF in primary antiphospholipid syndrome, targets for therapy?","volume":"12","author":"van den Hoogen","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1535","doi-asserted-by":"crossref","first-page":"141","DOI":"10.21037\/tcr.2017.02.39","article-title":"Heparin-induced thrombocytopenia: new insights into the immune response","volume":"6","author":"Cosmi","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1540","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.2147\/IJGM.S420327","article-title":"Heparin induced thrombocytopenia \u2013 pathophysiology, diagnosis and treatment: a narrative review","volume":"16","author":"Alhanshani","year":"2023","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1545","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.jtha.2023.08.014","article-title":"Fibrinogen and fibrin: synthesis, structure, and function in health and disease","volume":"21","author":"Wolberg","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1550","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1161\/01.CIR.0000131160.94926.6E","article-title":"C-reactive protein promotes monocyte chemoattractant protein-1\u2014mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes","volume":"109","author":"Han","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1555","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.0000052617.91920.FD","article-title":"C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis","volume":"107","author":"Devaraj","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1560","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1565","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.CIR.0000114526.50618.24","article-title":"C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E\u2013deficient mice","volume":"109","author":"Paul","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1570","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/03630269.2023.2301026","article-title":"Hypercoagulability in sickle cell disease: a thrombo-inflammatory mechanism","volume":"47","author":"Hamali","year":"2023","journal-title":"Hemoglobin"},{"key":"10.1016\/j.pharma.2024.08.005_bib1575","doi-asserted-by":"crossref","first-page":"18205","DOI":"10.1016\/S0021-9258(19)81346-7","article-title":"Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity","volume":"263","author":"Sims","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharma.2024.08.005_bib1580","doi-asserted-by":"crossref","first-page":"183382","DOI":"10.1016\/j.bbamem.2020.183382","article-title":"Physiological roles of transverse lipid asymmetry of animal membranes","volume":"1862","author":"Clarke","year":"2020","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.pharma.2024.08.005_bib1585","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jim-2019-001195","article-title":"Platelets and platelet extracellular vesicles in hemostasis and sepsis","volume":"68","author":"Kerris","year":"2020","journal-title":"J Investig Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1590","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell\u2013derived ultralarge von Willebrand factor multimers under flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1595","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cells10123517","article-title":"Pleiotropic effects of the protease-activated receptor 1 (PAR1) inhibitor, vorapaxar, on atherosclerosis and vascular inflammation","volume":"10","author":"Friebel","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharma.2024.08.005_bib1600","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00003246-200009001-00008","article-title":"Therapeutic rationale for antithrombin III in sepsis","volume":"28","author":"Opal","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1605","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.atherosclerosis.2020.06.003","article-title":"Tissue factor in atherosclerosis and atherothrombosis","volume":"307","author":"Grover","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1610","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a \u03b23 integrin\u2013dependent mechanism","volume":"8","author":"Andre","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1615","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1242\/dev.128.6.827","article-title":"Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block","volume":"128","author":"Isermann","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.pharma.2024.08.005_bib1620","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood.V94.10.3413.422k24_3413_3420","article-title":"Tissue factor and factor VIIa receptor\/ligand interactions induce proinflammatory effects in macrophages","volume":"94","author":"Cunningham","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1625","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/cells12222621","article-title":"Neutrophils in inflammatory diseases: unraveling the impact of their derived molecules and heterogeneity","volume":"12","author":"Riaz","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.pharma.2024.08.005_bib1630","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0735-1097(00)01110-4","article-title":"Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes","volume":"37","author":"Aukrust","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1635","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0002-8703(93)90526-F","article-title":"Elevated plasma interleukin-6 levels in patients with acute myocardial infarction","volume":"126","author":"Miyao","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1640","doi-asserted-by":"crossref","first-page":"33","DOI":"10.47144\/phj.v56i1.2468","article-title":"The role of high-sensitive C-reactive protein in predicting severity of coronary artery disease in patients with acute coronary syndromes","volume":"56","author":"Kiani","year":"2023","journal-title":"Pak Heart J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1645","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0735-1097(98)00136-3","article-title":"C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy","volume":"31","author":"Morrow","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1650","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1655","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0195-668X(03)00200-8","article-title":"Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment","volume":"24","author":"Dibra","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1660","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/jpet.102.040600","article-title":"C-reactive-protein-associated increase in myocardial infarct size after ischemia\/reperfusion","volume":"303","author":"Barrett","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2024.08.005_bib1665","doi-asserted-by":"crossref","first-page":"109781","DOI":"10.1016\/j.intimp.2023.109781","article-title":"Characteristics and pathogenesis of chemokines in the post-stroke stage","volume":"116","author":"Lin","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1670","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/19546","article-title":"MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions","volume":"398","author":"Gerszten","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2024.08.005_bib1675","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1079\/PNS2004378","article-title":"Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls","volume":"63","author":"Minnich","year":"2004","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.pharma.2024.08.005_bib1680","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1172\/JCI1195","article-title":"A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice","volume":"101","author":"Boisvert","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2024.08.005_bib1685","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/bjc.1998.373","article-title":"Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma","volume":"77","author":"Leek","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.pharma.2024.08.005_bib1690","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9150(99)00463-3","article-title":"Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?","volume":"148","author":"Yudkin","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1695","doi-asserted-by":"crossref","first-page":"12653","DOI":"10.3390\/ijms241612653","article-title":"Pharmacology and rationale for seralutinib in the treatment of pulmonary arterial hypertension","volume":"24","author":"Pullamsetti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1700","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.atherosclerosis.2006.02.034","article-title":"Cytokine profiles and T cell function in acute coronary syndromes","volume":"190","author":"Steppich","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1705","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","article-title":"Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity","volume":"17","author":"Neumann","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1710","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0021-9150(97)00132-9","article-title":"Localization and activity of tissue factor in human aortic atherosclerotic lesions","volume":"133","author":"Hatakeyama","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1715","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.blre.2013.03.001","article-title":"The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis","volume":"27","author":"Winckers","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1720","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V97.12.3721","article-title":"Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1","volume":"97","author":"Ott","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1725","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nm841","article-title":"Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein","volume":"9","author":"Bogdanov","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1730","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.RES.0000171805.24799.fa","article-title":"Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines","volume":"96","author":"Szotowski","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1735","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1073\/pnas.96.5.2311","article-title":"Blood-borne tissue factor: another view of thrombosis","volume":"96","author":"Giesen","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharma.2024.08.005_bib1740","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0002-9149(97)00801-1","article-title":"Comparison of plasma tissue factor levels in unstable and stable angina pectoris","volume":"81","author":"Misumi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1745","doi-asserted-by":"crossref","first-page":"719","DOI":"10.33549\/physiolres.930286","article-title":"Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome","volume":"52","author":"Maly","year":"2003","journal-title":"Physiol Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1750","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.thj.6200415","article-title":"Relations between hemostatic variables, insulin resistance and inflammation","volume":"5","author":"Morange","year":"2004","journal-title":"Hematology J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-7-11","article-title":"Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction","volume":"7","author":"Steppich","year":"2009","journal-title":"Thromb J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1760","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0002-9440(10)64824-9","article-title":"Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation","volume":"157","author":"Erlich","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1765","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/01.RES.0000177533.48483.12","article-title":"Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor","volume":"97","author":"Ott","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1770","doi-asserted-by":"crossref","first-page":"216221","DOI":"10.1016\/j.canlet.2023.216221","article-title":"Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function","volume":"565","author":"Ren","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharma.2024.08.005_bib1775","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0049-3848(07)70128-7","article-title":"Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?","volume":"120","author":"White","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1780","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"Ahmadi","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1785","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis","volume":"105","author":"Yu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1790","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/01.CIR.0000153333.52294.42","article-title":"Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38","volume":"111","author":"Ott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib1795","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2006.10.010","article-title":"Differential functions of tissue factor in the trans-activation of cellular signalling pathways","volume":"194","author":"Ettelaie","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1800","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0049-3848(01)00404-2","article-title":"Elevated plasma levels of the factor Xa\u2013TFPI complex in cancer patients","volume":"105","author":"Iversen","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1805","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.jtha.2023.08.001","article-title":"Fibrinolytic pathophysiologies: still the poor cousin of hemostasis?","volume":"21","author":"Mutch","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1810","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1815","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1189\/jlb.0105024","article-title":"Regulated expression of platelet factor 4 in human monocytes\u2014role of PARs as a quantitatively important monocyte activation pathway","volume":"78","author":"Schaffner","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1820","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/01.ATV.0000151279.35780.2d","article-title":"Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction","volume":"25","author":"Busch","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1825","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.ATV.0000258862.61067.14","article-title":"Membrane-type serine protease-1\/matriptase induces interleukin-6 and-8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis","volume":"27","author":"Seitz","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1830","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jcp.2003.015156","article-title":"Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions","volume":"57","author":"Napoli","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1835","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/QCO.0b013e328344c078","article-title":"The effect of inflammation on coagulation and vice versa","volume":"24","author":"van der Poll","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1840","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1538-7836.2003.00300.x","article-title":"Specificity of coagulation factor signaling","volume":"1","author":"Ruf","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1845","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2009-09-201616","article-title":"The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications","volume":"115","author":"Danese","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1850","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1182\/blood-2008-12-192385","article-title":"Endogenous EPCR\/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality","volume":"113","author":"Niessen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1855","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20070404","article-title":"Endotoxemia and sepsis mortality reduction by non-anticoagulant\u2013activated protein C","volume":"204","author":"Kerschen","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1860","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1172\/JCI40380","article-title":"The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b","volume":"120","author":"Cao","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2024.08.005_bib1865","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1378\/chest.124.3_suppl.18S","article-title":"Thrombin and platelet activation","volume":"124","author":"Brass","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pharma.2024.08.005_bib1870","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jtha.2023.01.027","article-title":"JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte\u2013endothelial proadhesive interactions","volume":"21","author":"Beckman","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib1875","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","article-title":"Proteinase-activated receptors","volume":"53","author":"Macfarlane","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharma.2024.08.005_bib1880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-024-02986-z","article-title":"The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease","volume":"25","author":"Ali","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1885","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00001721-199909000-00001","article-title":"Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation","volume":"10","author":"Ohkura","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.pharma.2024.08.005_bib1890","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1378\/chest.14-2028","article-title":"The association of direct thrombin inhibitor anticoagulants with cardiac thromboses","volume":"147","author":"Davidson","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.pharma.2024.08.005_bib1895","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM199703203361207","article-title":"Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction","volume":"336","author":"Collins","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1900","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(17)31441-1","article-title":"Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis","volume":"390","author":"Jinatongthai","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2024.08.005_bib1905","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2024.08.005_bib1910","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharma.2024.08.005_bib1915","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood.V97.10.3109","article-title":"Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1","volume":"97","author":"Riewald","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1920","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2003-10-3417","article-title":"Tissue factor-factor VIIa\u2013specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration","volume":"103","author":"Hjortoe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1925","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-6363(01)00452-7","article-title":"Tissue factor and coronary artery disease","volume":"53","author":"Moons","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1930","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.1158\/0008-5472.CAN-06-1803","article-title":"Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII","volume":"66","author":"Koizume","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1935","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/ATVBAHA.108.177428","article-title":"Tissue factor and PAR2 signaling in the tumor microenvironment","volume":"29","author":"Schaffner","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1940","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.neuroscience.2009.11.049","article-title":"Inhibition of tissue factor\/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells","volume":"165","author":"Gessler","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharma.2024.08.005_bib1945","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jss.2008.05.014","article-title":"Inhibition of tissue factor\u2014factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer","volume":"153","author":"Zerbib","year":"2009","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib1950","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1955","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/eji.202149410","article-title":"Innate immune signaling and immunothrombosis: new insights and therapeutic opportunities","volume":"52","author":"Ryan","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharma.2024.08.005_bib1960","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/jcm12041399","article-title":"Immunothrombosis: molecular aspects and new therapeutic perspectives","volume":"12","author":"Marcos-Jubilar","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1965","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1970","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.3390\/jcm9092942","article-title":"Neutrophil extracellular traps and by-products play a key role in COVID-19: pathogenesis, risk factors, and therapy","volume":"9","author":"Thierry","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1975","doi-asserted-by":"crossref","first-page":"863846","DOI":"10.3389\/fcvm.2022.863846","article-title":"Implication of platelets in immuno-thrombosis and thrombo-inflammation","volume":"9","author":"Zaid","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib1980","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.3390\/ijms22157894","article-title":"Platelet innate immune receptors and TLRs: a double-edged sword","volume":"22","author":"Ebermeyer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1985","doi-asserted-by":"crossref","first-page":"12563","DOI":"10.3390\/ijms241612563","article-title":"The crossroads of the coagulation system and the immune system: interactions and connections","volume":"24","author":"Wilhelm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib1990","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2012-06-437392","article-title":"Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice","volume":"121","author":"Duerschmied","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib1995","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2022.11.026","article-title":"Therapy with high-dose statins reduces soluble P-selectin: the impact on plasma fibrin clot properties","volume":"373","author":"Siudut","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib2000","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1038\/ncomms15559","article-title":"Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIb\u03b1","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharma.2024.08.005_bib2005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib2010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jvs.2005.04.045","article-title":"Decreased venous thrombosis with an oral inhibitor of P selectin","volume":"42","author":"Myers","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pharma.2024.08.005_bib2015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.103.4.491","article-title":"Soluble P-selectin and the risk of future cardiovascular events","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib2020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jth.12571","article-title":"Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development","volume":"12","author":"Savchenko","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib2025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","article-title":"P-selectin promotes neutrophil extracellular trap formation in mice","volume":"126","author":"Etulain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2030","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2016-04-710632","article-title":"Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice","volume":"128","author":"Stark","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2035","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1111\/jth.12710","article-title":"Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps","volume":"12","author":"Maugeri","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib2040","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2013-07-516484","article-title":"Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap\u2013mediated sterile inflammation","volume":"123","author":"Rossaint","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2045","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3390\/ijms25053025","article-title":"Traps in response to infection or inflammation, and the roles of platelet interactions","volume":"25","author":"Chen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib2050","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood-2011-03-343061","article-title":"Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4","volume":"118","author":"Semeraro","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2055","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib2060","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2018-10-862243","article-title":"Neutrophils: back in the thrombosis spotlight","volume":"133","author":"Noubouossie","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2065","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-018-03925-2","article-title":"Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation","volume":"9","author":"Pircher","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharma.2024.08.005_bib2070","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCRESAHA.112.265868","article-title":"Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice","volume":"110","author":"D\u00f6ring","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2024.08.005_bib2075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002531","article-title":"Neutrophil-derived cathelicidin protects from neointimal hyperplasia","volume":"3","author":"Soehnlein","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib2080","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1084\/jem.20161070","article-title":"Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease","volume":"214","author":"Uderhardt","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib2085","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/1076029609348647","article-title":"Eosinophilia and thrombophilia in Churg Strauss syndrome: a clinical and pathogenetic overview","volume":"16","author":"Ames","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.pharma.2024.08.005_bib2090","doi-asserted-by":"crossref","first-page":"e111862","DOI":"10.1371\/journal.pone.0111862","article-title":"Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis","volume":"9","author":"Cugno","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.pharma.2024.08.005_bib2095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004658","article-title":"Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: a case report and literature review","volume":"95","author":"Gao","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.pharma.2024.08.005_bib2100","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019000518","article-title":"Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps","volume":"134","author":"Marx","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2024.08.005_bib2105","first-page":"1","article-title":"Eosinophil extracellular traps in respiratory ailment: pathogenic mechanisms and clinical translation","volume":"9","author":"Wu","year":"2023","journal-title":"World J Otorhinolaryngol-Head Neck Surg"},{"key":"10.1016\/j.pharma.2024.08.005_bib2110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib2115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jointm.2023.07.006","article-title":"Antimicrobial stewardship and targeted therapies in the changing landscape of maternal sepsis","volume":"4","author":"Shah","year":"2024","journal-title":"J Intensive Med"},{"key":"10.1016\/j.pharma.2024.08.005_bib2120","first-page":"279","article-title":"Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha)","volume":"30","author":"Hinshaw","year":"1990","journal-title":"Circul Shock"},{"key":"10.1016\/j.pharma.2024.08.005_bib2125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-018-0187-6","article-title":"The impact of septic stimuli on the systemic inflammatory response and physiologic insult in a preclinical non-human primate model of polytraumatic injury","volume":"15","author":"Vicente","year":"2018","journal-title":"J Inflamm"},{"key":"10.1016\/j.pharma.2024.08.005_bib2130","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/BF02088576","article-title":"Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver","volume":"41","author":"Hisama","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharma.2024.08.005_bib2135","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0002-9149(03)00148-6","article-title":"Meta-analysis of corticosteroid treatment in acute myocardial infarction","volume":"91","author":"Giugliano","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharma.2024.08.005_bib2140","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2024.08.005_bib2145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000056183","article-title":"A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules","volume":"65","author":"Manduteanu","year":"2002","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharma.2024.08.005_bib2150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","article-title":"Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non\u2013ST-segment elevation acute myocardial infarction (the ARMADA study)","volume":"91","author":"Montalescot","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T02:29:33Z","timestamp":1739672973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":231,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0003450924001123"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.08.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}